Neratinib

Independent reference data for Neratinib (CAS 698387-09-6), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.Neratinib is an orally available tyrosine kinase receptor inhibitor that is used in the extended adjuvant therapy of early stage breast cancer. Neratinib is associated with a low rate of transient elevations in serum aminotransferase levels during therapy, but has not been convincingly linked to cases of clinically apparent liver injury with jaundice.

Synonyms and trade names

Neratinib; 698387-09-6; HKI-272; HKI 272; JJH94R3PWB; PB-272; CHEBI:61397; CDP-820; PB 272; HKI272; DTXSID70220132; N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide; neratinibum; RefChem:56993; DTXCID70142623; L10XE45

Regulatory listings held on file

GHS notification summary	20% (1 / 5)

GHS hazard classification

GHS notification summary	20% (1 / 5)
Reported hazard statements	H302 (40%), H312 (40%), H315 (40%), H319 (40%), H332 (40%), H335 (20%), H360 (40%)

This chemical does not meet GHS hazard criteria for 20% (1 of 5) of reports.

H302 (40%): Harmful if swallowed [Warning Acute toxicity, oral]

What the public record says

Neratinib · CAS 698387-09-6 · C30H29ClN6O3. UNII JJH94R3PWB.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.